Discontinued — last reported Q1 '18
Entegris Allowance for Doubtful Accounts Receivable (Current) decreased by 6.3% to $4.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 95.7%, from $2.30M to $4.50M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 15.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.23M | $2.36M | $2.35M | $2.49M | $3.16M | $4.30M | $5.44M | $5.34M | $4.38M | $4.13M | $6.41M | $5.89M | $5.51M | $4.90M | $3.10M | $2.30M | $3.80M | $3.10M | $4.80M | $4.50M |
| QoQ Change | — | +5.9% | -0.3% | +5.8% | +27.2% | +36.2% | +26.5% | -1.9% | -17.9% | -5.9% | +55.4% | -8.1% | -6.5% | -11.0% | -36.7% | -25.8% | +65.2% | -18.4% | +54.8% | -6.3% |
| YoY Change | — | — | — | — | +42.1% | +82.7% | +131.7% | +114.8% | +38.7% | -4.1% | +17.8% | +10.3% | +25.7% | +18.8% | -51.7% | -61.0% | -31.0% | -36.7% | +54.8% | +95.7% |